Chardan analyst Daniil Gataulin downgraded Oyster Point Pharma (OYST) to Neutral from Buy with a price target of $13, down from $22, after the company agreed to be acquired by Viatris (VTRS).
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VTRS:
- Here’s Why Viatris (NASDAQ:VTRS) Shares Soared 13% Recently
- Ocuphire Pharma enters exclusive license agreement with FamyGen Life Sciences
- Early notable gainers among liquid option names on November 7th
- Viatris to acquire Oyster Point Pharma and Famy Life Sciences
- Viatris to acquire Oyster Point for $11 per share plus CVR up to $2.00 per share
